Open AccessTargeted therapy in the treatment of HER-2 positive breast cancer with brain metastases
Author(s) -
Д. Р. Насхлеташвили,
К. Е. Рощина,
Vera Gorbunova,
T. G. Gasparyan,
М. Б. Бычков,
А. Kh. Bekyashev,
В. Б. Карахан,
Е. А. Москвина,
В. А. Алешин,
Д. М. Белов,
А. А. Митрофанов,
Е. В. Прозоренко,
Asmik A. Pogosova
Publication year - 2020
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.17816/1028-9984-2020-25-4-146-153
Subject(s) - medicine , breast cancer , metastatic breast cancer , targeted therapy , brain metastasis , oncology , cancer , chemotherapy , metastasis , systemic therapy
Metastatic damage to the brain is a frequent manifestation in tumors of various localizations, including breast cancer. Until recently, systemic therapy of metastatic brain damage was of limited use; however, with the advent of targeted drugs that are better understood in terms of the specific molecular targets and biological characteristics of metastases, it is now possible to improve treatment results. In an analysis of the results of studies on the problem of metastasis of breast cancer in the brain, a comparison of the use of various targeted drugs in the treatment of metastatic HER2 + breast cancer is presented. The results of a comparison of the degrees of effectiveness of targeted drugs, both in monotherapy and in combination with chemotherapy, were obtained and analyzed.